Lack of Association between the COMT rs4680 Polymorphism and Ovarian Cancer Risk: Evidence from a Meta-analysis of 3,940 Individuals

  • Du, Jin-Ze (Department of Pathology, Shihezi University School of Medicine) ;
  • Dong, Yu-Ling (Department of Pathology, Shihezi University School of Medicine) ;
  • Wan, Guo-Xing (Department of Pathology, Shihezi University School of Medicine) ;
  • Tao, Lin (Department of Pathology, Shihezi University School of Medicine) ;
  • Lu, Li-Xia (Department of Pathology, Shihezi University School of Medicine) ;
  • Li, Feng (Department of Pathology, Shihezi University School of Medicine) ;
  • Pang, Li-Juan (Department of Pathology, Shihezi University School of Medicine) ;
  • Jia, Wei (Department of Pathology, Shihezi University School of Medicine)
  • 발행 : 2014.10.11


Catechol-O-methyltransferase (COMT) is involved in estrogen metabolism and is vital to estrogen-induced carcinogenesis, including that of ovarian cancer. Although many recent epidemiologic studies have investigated associations between the COMT rs4680 polymorphism and ovarian cancer risk, the results remain inconclusive. We therefore performed a meta-analysis to derive a more precise estimate of associations. Systematic searches of the PubMed, Embase, Web of Science, Cochrane Library, Wanfang, China National Knowledge Infrastructure, and Chinese Biomedicine databases were undertaken to retrieve eligible studies. Odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) were pooled to assess the strength of the association. In total, 8 case-control studies involving 1,293 cases and 2,647 controls were included in the meta-analysis. Overall, the results showed no evidence of significant association between the COMT rs4680 polymorphism and ovarian cancer risk in any of the assessed genetic models. Subgroup analyses by ethnicity also did not reveal any significant association in any genetic model (p>0.05). In conclusion, our findings suggest that the COMT rs4680 polymorphism may not contribute to the risk of ovarian cancer.


  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 1088-101.
  2. Chan KK-L, Leung TH-Y, Chan DW, et al (2014). Targeting estrogen receptor subtypes (ER$\alpha$ and ER$\beta$) with selective ER modulators in ovarian cancer. J Endocrinol, 221, 325-36.
  3. Cochran WG (1950). The comparison of percentages in matched samples. Biometrika, 256-66.
  4. Dawling S, Roodi N, Mernaugh RL, et al (2001). Catechol-Omethyltransferase (COMT)-mediated metabolism of catechol estrogens comparison of wild-type and variant COMT isoforms. Cancer Res, 61, 6716-22.
  5. Delort L, Chalabi N, Satih S, et al (2008). Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res, 28, 3079-81.
  6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  7. Egger M, Smith GD, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.
  8. Emori MM, Drapkin R (2014). The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol, 12, 60.
  9. Grossman M, Emanuel B, Budarf M (1992). Chromosomal mapping of the human catechol- O-methyltransferase gene to 22q11. 1g q11. 2. Genomics, 12, 822-5.
  10. Garner EI, Stokes EE, Berkowitz RS, et al (2002). Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res, 62, 3058-62.
  11. Goodman JE, Lavigne JA, Hengstler JG, et al (2000). Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiol Biomarkers Prev, 9, 1373-6.
  12. Goodman MT, McDuffie K, Kolonel LN, et al (2001). Casecontrol study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev, 10, 209-16.
  13. Guldberg HC, Marsden CA (1975). Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev, 27, 135-206.
  14. He X-F, Wei W, Li S-X, et al (2012). Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls. Mol Biol Rep, 39, 6811-23.
  15. Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  16. Higgins J, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. Bmj, 327, 557-60.
  17. Hirata H, Hinoda Y, Okayama N, et al (2008). COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol carcinog, 47, 768-74.
  18. Holt SK, Rossing MA, Malone KE, et al (2007). Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev, 16, 481-9.
  19. Liu X-H, Man Y-N, Wu X-Z (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32.
  20. Jakubowska A, Gronwald J, Menkiszak J, et al (2010). BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat, 119, 201-11.
  21. Lachman HM, Papolos DF, Saito T, et al (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenet Genomics, 6, 243-50.
  22. Lin G, Zhao J, Wu J, et al (2012). Contribution of catechol-Omethyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis. Genet Mol Res, 12, 6442-53.
  23. Mannisto P, Ulmanen I, Lundstrom K, et al (1992). Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res, 39, 291-350
  24. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  25. Mao C, Wang X-W, Qiu L-X, et al (2010). Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls. Breast Cancer Res Treat, 121, 719-25.
  26. Schüler S, Lattrich C, Skrzypczak M, et al (2014a). Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer. J Ovarian Res, 7, 42.
  27. Schüler S, Lattrich C, Skrzypczak M, et al (2014b). Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer. Gene, 546, 283-7.
  28. Weinshilboum RM, Raymond FA (1977). Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet, 29, 125.
  29. Sellers TA, Schildkraut JM, Pankratz VS, et al (2005). Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev, 14, 2536-43.
  30. Tian C, Liu L, Yang X, et al (2014). The Val 158 Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population. Tumor Biol, 35, 3003-8.
  31. Wan G-X, Cao Y-W, Li W-Q, et al (2014). The Catechol-OMethyltransferase Val158Met Polymorphism Contributes to the Risk of Breast Cancer in the Chinese Population: An Updated Meta-Analysis. J Breast Cancer, 17, 149-56.

피인용 문헌

  1. Contribution of Macrophage Migration Inhibitory Factor -173G/C Gene Polymorphism to the Risk of Cancer in Chinese Population vol.16, pp.11, 2015,
  2. Analysis of the Association of Matrix Metalloproteinase-1 Gene Promoter (rs1799750) Polymorphism and Risk of Ovarian Cancer vol.25, pp.6, 2015,
  3. The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols vol.49, pp.1, 2017,